Skip to main content
. 2022 Aug 9;6(24):6219–6227. doi: 10.1182/bloodadvances.2022008028

Figure 4.

Figure 4.

Time to relapse in patients treated with caplacizumab + rituximab vs patients treated with caplacizumab alone (n = 75∗). (It should be noted that all patients also received PEX and corticosteroids.) ∗Two patients were lost to follow-up in the caplacizumab + rituximab group. Capla, caplacizumab.